Induction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal influenza a viruses that are directed toward the nucleoprotein

Journal of Infectious Diseases

Volumn 215, Issue 5, 2017, Pages 818-823

  Jegaskanda, Sinthujan ^a,b   Co, Mary Dawn T ^c   Cruz, John ^d   Subbarao, Kanta ^a   Ennis, Francis A ^c   Terajima, Masanori ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^c Division of Infectious Diseases   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

ADCC; Antibody; Antibody dependent cellular cytotoxicity; Influenza virus; Nucleoprotein

Indexed keywords

CROSS REACTING ANTIBODY; HEMAGGLUTININ; SIALIDASE; VIRUS NUCLEOPROTEIN; CORE PROTEIN; INFLUENZA VACCINE; NP PROTEIN, INFLUENZA A VIRUS; RECOMBINANT PROTEIN; RNA BINDING PROTEIN; VIRUS ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; HUMAN; HUMAN CELL; INFLUENZA A (H7N9); INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H7N9); LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; ADOLESCENT; ADULT; BLOOD; CHILD; CROSS REACTION; IMMUNOLOGY; INFANT; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; HEMAGGLUTININS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; KILLER CELLS, NATURAL; MIDDLE AGED; NEURAMINIDASE; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; VIRAL CORE PROTEINS; YOUNG ADULT;

EID: 85019104936     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw629     Document Type: Article

References (28)

1. World Health Organization. WHO risk assessment of human infections with avian influenza A(H7N9) virus. http://www.who.int/influenza/ human-animal-interface/influenza-h7n9/RiskAssessment-H7N9-23Feb20115. pdf. Accessed 27 Septemeber 2016
2. Sobhanie M, Matsuoka Y, Jegaskanda S, et al. Evaluation of the safety and immunogenicity of a candidate pandemic live attenuated influenza vaccine (pLAIV) against influenza A(H7N9). J Infect Dis 2016; 213:922-9
3. Jackson LA, Campbell JD, Frey SE, et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. JAMA 2015; 314:237-46
4. Rudenko L, Isakova-Sivak I, Naykhin A, et al. H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis 2016; 16:303-10
5. Vanderven HA, Ana-Batiz F, Jegaskanda S, et al. What lies beneath: antibody dependent natural killer cell activation by antibodies to internal influenza virus proteins. EBioMedicine 2016; 8:277-90
6. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001; 166:7381-8
7. Terajima M, Cruz J, Co MD, et al. Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol 2011; 85:13463-7
8. Jegaskanda S, Reading PC, Kent SJ. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J Immunol 2014; 193:469-75
9. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 2014; 20:143-51
10. Impagliazzo A, Milder F, Kuipers H, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015; 349:1301-6
11. DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 2016; 126:605-10
12. Jegaskanda S, Luke C, Hickman HD, et al. Generation and protective ability of influenza virus-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection, and experimental challenge. J Infect Dis 2016; 214:945-52
13. Jegaskanda S, Vandenberg K, Laurie KL, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. J Infect Dis 2014; 210:1811-22
14. Terajima M, Co MD, Cruz J, Ennis FA. High antibody-dependent cellular cytotoxicity antibody titers to H5N1 and H7N9 avian influenza A viruses in healthy US adults and older children. J Infect Dis 2015; 212:1052-60
15. Jegaskanda S, Job ER, Kramski M, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013; 190:1837-48
16. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983; 148:785-94
17. Hashimoto G, Wright PF, Karzon DT. Ability of human cord blood lymphocytes to mediate antibody-dependent cellular cytotoxicity against influenza virus-infected cells. Infect Immun 1983; 42:214-8
18. Quinnan GV, Ennis FA, Tuazon CU, et al. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun 1980; 30:362-9
19. Henry Dunand CJ, Leon PE, Huang M, et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe 2016; 19:800-13
20. Ahmed SS, Volkmuth W, Duca J, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor. 2. Sci Transl Med 2015; 7:294ra105
21. Fujimoto Y, Tomioka Y, Takakuwa H, et al. Cross-protective potential of anti-nucleoprotein human monoclonal antibodies against lethal influenza A virus infection. J Gen Virol 2016; 97:2104-16
22. Bullido R, Gomez-Puertas P, Albo C, Portela A. Several protein regions contribute to determine the nuclear and cytoplasmic localization of the influenza A virus nucleoprotein. J Gen Virol 2000; 81(Pt 1):135-42
23. Yewdell JW, Frank E, Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 1981; 126:1814-9
24. Bodewes R, Geelhoed-Mieras MM, Wrammert J, et al. In vitro assessment of the immunological significance of a human monoclonal antibody directed to the influenza a virus nucleoprotein. Clin Vaccine Immunol 2013; 20:1333-7
25. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008; 181:4168-76
26. LaMere MW, Lam HT, Moquin A, et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 2011; 186:4331-9
27. Hassane M, Paget C. "Universal flu vaccine": Can NK cell-mediated ADCC tip the scales? EBioMedicine 2016; 8:18-9
28. Zhong W, Reed C, Blair PJ, Katz JM, Hancock K, Influenza serology working G. Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. J Infect Dis 2014; 209:986-94